| Market Cap | $7.04B+296.3% |
| Revenue (ttm) | $459.43M |
| Net Income | -$130.20M |
| EPS | -$2.08 |
| Shares Out | 68.18M |
| PE Ratio | n/a |
| Forward PE | 1581.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,378,941 |
| Open | $108.39 |
| Previous Close | $111.62 |
| Day's Range | $101.00 - $108.50 |
| 52-Week Range | $25.67 - $219.71 |
| Beta | 2.22 |
| Analysts | Buy |
| Price Target | $128.82(+24.68%) |
| Earnings Date | Feb 1, 2027 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating TWST in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 1, 2027Earnings report
$TWST stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TWST holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TWST's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TWST Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TWST Revenue by Segment or Geography
| NGS Applications | $237.54M | 51.70% |
| DNA Synthesis and Protein Solutions | $221.89M | 48.30% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-K)
U.S. Patents
New TWST patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TWST from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TWST
| IWMiShares Russell 2000 ETF | $256.65M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TWST’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst downgrade offset by strong Q4 earnings with record revenue and positive guidance; valuation concerns temper gains.
Recent Insider Activity
Insider Score Trend Over Time
-36.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| ARKG | ARK Genomic Revolution ETF | 7.65% |
| GNOM | Global X - Genomics & Biotechnology ETF | 5.55% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 4.94% |
| HLTH | Tema Healthcare AI ETF | 4.47% |
| RKNG | ETF Series Solutions - Defiance Retail Kings ETF | 3.51% |
| EDOC | Global X Telemedicine & Digital Health ETF | 3.20% |
| HELX | Franklin Genomic Advancements ETF | 3.18% |
| WDNA | WisdomTree BioRevolution Fund | 3.00% |
| ARKK | ARK Innovation ETF | 2.94% |
| FRTY | Alger Mid Cap 40 ETF | 2.76% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 2.41% |
| HAPS | Harbor Human Capital Factor US Small Cap ETF | 2.02% |
Weight is the stock’s share of each fund’s holdings.
